Antiplatelet drugs Flashcards

1
Q

Aspirin - MOA of antiplatelet effect

A

In low doses aspirin selectively inhibits thromboxane A2 (TXA2) synthesis (promotes aggregation). Prostacyclin (platelet aggregation inhibiting) inhibition: higher doses.
Irreversible inhibition of COX.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Aspirin - indications

A

Ischemic heart disease & stroke: Secondary prevention.
Angina: prevent MI
Primary prevention: men>45, women>55 with risk factors for heart disease/stroke (diabetes).
Acute MI, TIA (prevent stroke), artificial heart valves, percutaneous coronary angioplasty.
Peripheral occlusive disease, chronic limb ischemia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Aspirin - adverse effects

A

Bleeding (esp GI, inhibition of prostaglandins = inhibition of bicarbonate & mucus secretion).
High doses: hypoprothrombinemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Antiplatelet drugs - 3 drugs, 2 groups

A
Aspirin
Dipyridamole
Cilostazol
ADP inhibitors
Glycoprotein IIb/IIIa antagonists
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Dipyridamole - MOA

A

Coronary vasodilator and weak antiplatelet.
Inhibits platelet adhesion to the vessel wall, and platelet aggregation (latter by increasing cAMP and decreasing Ca in platelets)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Dipyridamole - indications

A

Vasodilation: myocardial perfusion imaging (thallium imaging).
Antiplatelet: with aspirin for prevention of ischemic (thrombotic) stroke in pts who had this or have TIA.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Cilostazol - MOA

A

Inhibits phosphodiesterase III and increase cAMP in platelets & blood vessels. This causes vasodilation and inhibition of platelet aggregation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Cilostazol - Indications

A

Intermittent claudication (limb weakness & pain)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Cilostazol - interactions

A

Metabolized by CYP3A4 (e.g. erythromycin may increase antiplatelet effect)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

ADP inhibitors - 4 drugs

A

Clopidogrel
Prasugrel
Ticlopidine
Ticagrelor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

ADP inhibitors - interactions

A

Ticlopidine, clopidogrel, prasugrel: metabolized into active metabolite by CYPs.
Clopidogrel: activation is potentially inhibited by PPI (but they can be given together).
Ticagrelor does not need activation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Which ADP inhibitor has greater potency?

A

Prasugrel

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

ADP inhibitors - MOA

A

Block ADP P2Y12 receptors and inhibits expression of GP IIb/IIIa receptors. This prevents ADP-induced platelet aggregation.
Clopidogrel, ticlopidine, prasugrel: irreversible antagonists.
Ticagrelor - reversible antagonists.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

When is ticagrelor better to use than other ADP-inhibitors

A

E.g. surgery - when irreversible inhibition is not needed.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Clopidogrel & prasugrel - indications

A

Pts who cannot take aspirin: Prevent thrombotic stroke.
With aspirin: ACS.
Clopidogrel also in: Intermittent claudication of blood vessels, chronic arterial occlusion, atrioventricular shunts/fistulas, open heart surgery, sickle cell anemia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Ticagrelor - indications

A

Prevention of thrombotic events in MI or STEMI (with aspirin unless contraindicated).

17
Q

Ticagrelor - adverse effects

A

Dyspnea

18
Q

Ticlopidine - adverse effects

A

Severe neutropenia (complete blood count evr 2 weeks).

19
Q

Glycoprotein IIb/IIIa antagonists - 3 drugs

A

Abciximab
Tirofiban
Eptifibatide

20
Q

GP IIb/IIIa antagonists - MOA

A

Binds to platelet GP IIb/IIIa reveptors and prevents fibrinogen to bind and crosslinking of platelets.
Tirofiban and eptifibatide: competitive, reversible inhibitors.

21
Q

Abciximab - indications

A

Combo with aspirin and heparin/LMWHs: Percutaneous coronary interventions (coronary angioplasty, stent placement).
Adjunct to thrombolysis

22
Q

Abciximab - adverse effects

A

Bleeding, thrombocytopenia, hypotension, bradycardia.

23
Q

Tirofiban and eptifibatide - indications

A

Unstable angina and MI (often combo with LMWHs).

Eptifibatide - STEMI, coronary angioplasty/stent placement

24
Q

Aspirin - interactions

A

Sulfonylureas: increased hypoglycemic effect.
Methotrexate, valproate: increased GI bleeding+ ulceration.
Probenecid: inhibits uricosuric effect.